Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bramlage

Showing results (81-90 of 429) with videos related to

Pageof 43
Sort By:
Blood Pressure Monitoring|November 1, 2016
Validation of the blood pressure measurement device Erkameter 125 PRO according to the European Society of Hypertension International Protocol revision 2010Beate Beime, Cornelia Deutsch, Ralf Krüger, et al.
Vascular Health and Risk Management|June 3, 2021
Risk Factor Management in Non-Metropolitan Patients with Coronary and Peripheral Artery Disease - A Protocol of a Prospective, Multi-Center, Quality Improvement StrategyClaudia Zemmrich, Peter Bramlage, Philipp Hillmeister, et al.
Clinical Drug Investigation|September 7, 2007
Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugsChristoph Schindler, Peter Bramlage, Martin Thoenes, et al.
Thrombosis Research|January 28, 2012
Bridging with the Low molecular weight heparin certoparin in patients requiring temporary discontinuation of oral anticoagulation - the non-interventional, retrospective REMEMBER studyRalf Eisele, Nima Melzer, Cornelia Englert, et al.
Medizinische Monatsschrift Fur Pharmazeuten|July 3, 2013
[Atrial fibrillation in Germany--epidemiology, diagnosis, treatment and costs]Karin Bramlage, Martin Thoenes, Ulrich Tebbe, et al.
Expert Review of Hematology|November 5, 2016
Betrixaban - the next direct factor Xa inhibitor?Martin Thoenes, Joan Minguet, Karin Bramlage, et al.
Expert Review of Clinical Pharmacology|November 8, 2016
The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillationJoan Minguet, Helen M Sims, Katherine H Smith, et al.
Journal of Clinical & Translational Endocrinology|November 13, 2018
A higher blood glucose level pre-breakfast in comparison to bedtime is a contraindication for intensification of prandial insulin therapy in patients with type 2 diabetes - The impact of a negative BeAM valueThorsten Siegmund, Anja Borck, Ariel Zisman, et al.
Blood Pressure Monitoring|January 20, 2025
Validation of the Microlife BP3T01-1B blood pressure monitoring device in adults and adolescents according to the ISO 81060-2:2018 protocolBeate Botta, Carsten Bramlage, Violetta Hachaturyan, et al.
BMC Cardiovascular Disorders|November 21, 2014
Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-upPeter Bramlage, Anselm K Gitt, Steffen Schneider, et al.
Pageof 43

Showing results (81-90 of 429) with videos related to

Sort By:
Pageof 43
Blood Pressure Monitoring|November 1, 2016
Validation of the blood pressure measurement device Erkameter 125 PRO according to the European Society of Hypertension International Protocol revision 2010Beate Beime, Cornelia Deutsch, Ralf Krüger, et al.
Vascular Health and Risk Management|June 3, 2021
Risk Factor Management in Non-Metropolitan Patients with Coronary and Peripheral Artery Disease - A Protocol of a Prospective, Multi-Center, Quality Improvement StrategyClaudia Zemmrich, Peter Bramlage, Philipp Hillmeister, et al.
Clinical Drug Investigation|September 7, 2007
Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugsChristoph Schindler, Peter Bramlage, Martin Thoenes, et al.
Thrombosis Research|January 28, 2012
Bridging with the Low molecular weight heparin certoparin in patients requiring temporary discontinuation of oral anticoagulation - the non-interventional, retrospective REMEMBER studyRalf Eisele, Nima Melzer, Cornelia Englert, et al.
Medizinische Monatsschrift Fur Pharmazeuten|July 3, 2013
[Atrial fibrillation in Germany--epidemiology, diagnosis, treatment and costs]Karin Bramlage, Martin Thoenes, Ulrich Tebbe, et al.
Expert Review of Hematology|November 5, 2016
Betrixaban - the next direct factor Xa inhibitor?Martin Thoenes, Joan Minguet, Karin Bramlage, et al.
Expert Review of Clinical Pharmacology|November 8, 2016
The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillationJoan Minguet, Helen M Sims, Katherine H Smith, et al.
Journal of Clinical & Translational Endocrinology|November 13, 2018
A higher blood glucose level pre-breakfast in comparison to bedtime is a contraindication for intensification of prandial insulin therapy in patients with type 2 diabetes - The impact of a negative BeAM valueThorsten Siegmund, Anja Borck, Ariel Zisman, et al.
Blood Pressure Monitoring|January 20, 2025
Validation of the Microlife BP3T01-1B blood pressure monitoring device in adults and adolescents according to the ISO 81060-2:2018 protocolBeate Botta, Carsten Bramlage, Violetta Hachaturyan, et al.
BMC Cardiovascular Disorders|November 21, 2014
Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-upPeter Bramlage, Anselm K Gitt, Steffen Schneider, et al.
Pageof 43